Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus IRBESARTAN HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus IRBESARTAN HYDROCHLOROTHIAZIDE.
FILSPARI vs IRBESARTAN HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Irbesartan is an angiotensin II receptor antagonist that selectively blocks AT1 receptors, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume.
200 mg orally once daily, with or without food.
Oral, 150 mg irbesartan/12.5 mg hydrochlorothiazide once daily, titrated to 300 mg irbesartan/25 mg hydrochlorothiazide once daily based on BP response.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Irbesartan: 11–15 hours terminal half-life; supports once-daily dosing with steady state by 3 days. Hydrochlorothiazide: 6–15 hours terminal half-life; prolonged in renal impairment (up to 20+ hours) requiring dose adjustment.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Irbesartan: primarily fecal (80%) via biliary excretion, with ~20% renal. Hydrochlorothiazide: primarily renal (≥95% as unchanged drug) via tubular secretion.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB